Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis.
Manfredi R, Maresca G, Baron RL, De Franco A, De Gaetano AM, Cotroneo AR, Pirovano G, Spinazzi A, Marano P.J Magn Reson Imaging 1998 Jul-Aug;8(4):862-7
To determine whether gadobenate
dimeglumine (BOPTA) will adequately enhance cirrhotic liver parenchyma,
and to document the enhancement patterns in cirrhosis, 14 cirrhotic
and 20 non-cirrhotic patients were evaluated before and 60-120
minutes after gadolinium-BOPTA. Proof of liver cirrhosis was biopsy
(6), surgical resection (3), and clinical follow-up (5). Enhancement
effects were compared quantitatively by determining the liver
signal-to-noise ratio (SNR) and signal enhancement in both populations.
Qualitatively assessment of the liver enhancement was performed
and classified as homogeneous or heterogeneous. Quantitative analysis:
cirrhotic liver parenchyma presented a higher increase in SNR
values, relative to non-cirrhotic liver parenchyma, on postcontrast
images. Likewise the signal enhancement of cirrhotic liver parenchyma
was superior to non-cirrhotic liver on T1-weighted SE images (P
= .02) and in-phase GRE images (P < .001). There was no statistical
difference on out-of-phase GRE images. Qualitative analysis: on
T1-weighted SE postcontrast images, cirrhotic liver parenchyma
showed a homogeneous enhancement in 7 patients and heterogeneous
in 7. Whereas on GRE images, cirrhotic parenchyma showed heterogeneous
enhancement in 9 patients and homogeneous in 5 patients. The heterogeneous
enhancement was due to the presence of hypointense nodules in
7 patients and hyperintense nodules in 2 patients. In conclusion,
our study has shown that the hepatobiliary contrast agent Gd-BOPTA
is effective in the cirrhotic liver, demonstrating an increased
liver enhancement compared with non-cirrhotic patients.
| Retour au texte | Sommaire |